|
1
|
Ma CY, Ji WT, Chueh FS, Yang JS, Chen PY,
Yu CC and Chung JG: Butein inhibits the migration and invasion of
SK-HEP-1 human hepatocarcinoma cells through suppressing the ERK,
JNK, p38 and uPA signaling multiple pathways. J Agric Food Chem.
59:9032–9038. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhan P, Qian Q and Yu LK: Serum VEGF level
is associated with the outcome of patients with hepatocellular
carcinoma: A meta-analysis. Hepatobiliary Surg Nutr. 2:209–215.
2013.PubMed/NCBI
|
|
3
|
Nakazaki H: Preoperative and postoperative
cytokines in patients with cancer. Cancer. 70:709–713. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Okamoto K, Ishida C, Ikebuchi Y, Mandai M,
Mimura K, Murawaki Y and Yuasa I: The genotypes of IL-1 beta and
MMP-3 are associated with the prognosis of HCV-related
hepatocellular carcinoma. Intern Med. 49:887–895. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jang JW, Oh BS, Kwon JH, You CR, Chung KW,
Kay CS and Jung HS: Serum interleukin-6 and C-reactive protein as a
prognostic indicator in hepatocellular carcinoma. Cytokine.
60:686–693. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Naugler WE and Karin M: NF-kappaB and
cancer-identifying targets and mechanisms. Curr Opin Genet Dev.
18:19–26. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mehlen P and Puisieux A: Metastasis: A
question of life or death. Nat Rev Cancer. 6:449–458. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Daniele A, Divella R, Quaranta M, Mattioli
V, Casamassima P, Paradiso A, Garrisi VM, Gadaleta CD,
Gadaleta-Caldarola G, Savino E, et al: Clinical and prognostic role
of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior
to and after transhepatic arterial chemo-embolization. Clin
Biochem. 47:184–190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen R, Cui J, Xu C, Xue T, Guo K, Gao D,
Liu Y, Ye S and Ren Z: The significance of MMP-9 over MMP-2 in HCC
invasiveness and recurrence of hepatocellular carcinoma after
curative resection. Ann Surg Oncol. 19 Suppl 3:S375–S384. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu YC, Chiang IT, Hsu FT and Hwang JJ:
Using NF-κB as a molecular target for theranostics in radiation
oncology research. Expert Rev Mol Diagn. 12:139–146. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen YJ, Yeh MH, Yu MC, Wei YL, Chen WS,
Chen JY, Shih CY, Tu CY, Chen CH, Hsia TC, et al: Lapatinib-induced
NF-kappaB activation sensitizes triple-negative breast cancer cells
to proteasome inhibitors. Breast Cancer Res. 15:R1082013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu JM, Sheng H, Saxena R, Skill NJ,
Bhat-Nakshatri P, Yu M, Nakshatri H and Maluccio MA: NF-kappaB
inhibition in human hepatocellular carcinoma and its potential as
adjunct to sorafenib based therapy. Cancer Lett. 278:145–155. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hsu FT, Liu YC, Chiang IT, Liu RS, Wang
HE, Lin WJ and Hwang JJ: Sorafenib increases efficacy of vorinostat
against human hepatocellular carcinoma through transduction
inhibition of vorinostat-induced ERK/NF-κB signaling. Int J Oncol.
45:177–188. 2014.PubMed/NCBI
|
|
14
|
Jin Y, Chen J, Feng Z, Fan W, Wang Y, Li J
and Tong D: The expression of Survivin and NF-κB associated with
prognostically worse clinicopathologic variables in hepatocellular
carcinoma. Tumour Biol. 35:9905–9910. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tietze MK, Wuestefeld T, Paul Y, Zender L,
Trautwein C, Manns MP and Kubicka S: IkappaBalpha gene therapy in
tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of
hepatocellular carcinomas. Cancer Gene Ther. 7:1315–1323. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hsu FT, Liu YC, Liu TT and Hwang JJ:
Curcumin sensitizes hepatocellular carcinoma cells to radiation via
suppression of radiation-induced NF-κB activity. Biomed Res Int.
2015:363–671. 2015. View Article : Google Scholar
|
|
17
|
Ravi S and Singal AK: Regorafenib: An
evidence-based review of its potential in patients with advanced
liver cancer. Core Evid. 17:81–87. 2014.
|
|
18
|
Tai WT, Chu PY, Shiau CW, Chen YL, Li YS,
Hung MH, Chen LJ, Chen PL, Su JC, Lin PY, et al: STAT3 mediates
regorafenib-induced apoptosis in hepatocellular carcinoma. Clin
Cancer Res. 20:5768–5776. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chiang IT, Liu YC, Wang WH, Hsu FT, Chen
HW, Lin WJ, Chang WY and Hwang JJ: Sorafenib inhibits TPA-induced
MMP-9 and VEGF expression via suppression of ERK/NF-kB pathway in
hepatocellular carcinoma cells. In Vivo. 26:671–681.
2012.PubMed/NCBI
|
|
20
|
Wang WH, Chiang IT, Ding K, Chung JG, Lin
WJ, Lin SS and Hwang JJ: Curcumin-induced apoptosis in human
hepatocellular carcinoma j5 cells: Critical role of
ca(+2)-dependent pathway. Evid Based Complement Alternat Med.
2012:5129072012.PubMed/NCBI
|
|
21
|
Liao CL, Lai KC, Huang AC, Yang JS, Lin
JJ, Wu SH, Wood W Gibson, Lin JG and Chung JG: Gallic acid inhibits
migration and invasion in human osteosarcoma U-2 OS cells through
suppressing the matrix metalloproteinase-2/−9, protein kinase B
(PKB) and PKC signaling pathways. Food Chem Toxicol. 50:1734–1740.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pikarsky E, Porat RM, Stein I, Abramovitch
R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and
Ben-Neriah Y: NF-kappaB functions as a tumour promoter in
inflammation-associated cancer. Nature. 431:461–466. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baud V and Karin M: Is NF-kappaB a good
target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov.
8:33–40. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pacifico F and Leonardi A: NF-kappaB in
solid tumors. Biochem Pharmacol. 72:1142–1152. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chiang IT, Liu YC, Hsu FT, Chien YC, Kao
CH, Lin WJ, Chung JG and Hwang JJ: Curcumin synergistically
enhances the radiosensitivity of human oral squamous cell carcinoma
via suppression of radiation-induced NF-κB activity. Oncol Rep.
4:1729–1737. 2014.
|
|
26
|
Huang S, Pettaway CA, Uehara H, Bucana CD
and Fidler IJ: Blockade of NF-kappaB activity in human prostate
cancer cells is associated with suppression of angiogenesis,
invasion, and metastasis. Oncogene. 20:4188–4197. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Carr BI, Cavallini A, Lippolis C,
D'Alessandro R, Messa C, Refolo MG and Tafaro A: Fluoro-Sorafenib
(Regorafenib) effects on hepatoma cells: Growth inhibition,
quiescence, and recovery. J Cell Physiol. 228:292–297. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen D, Wei L, Yu J and Zhang L:
Regorafenib inhibits colorectal tumor growth through PUMA-mediated
apoptosis. Clin Cancer Res. 20:3472–3484. 2014. View Article : Google Scholar : PubMed/NCBI
|
